Journal of Cancer Research and Clinical Oncology

, Volume 134, Issue 1, pp 59–65

An increase in cell number at completion of therapy may develop as an indicator of early relapse

Quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer
  • Katharina Pachmann
  • Robert Dengler
  • Kurt Lobodasch
  • Frank Fröhlich
  • Torsten Kroll
  • Matthias Rengsberger
  • Rene Schubert
  • Ulrich Pachmann
Original Paper

Abstract

Purpose

Treatment efficiency of adjuvant therapy in breast cancer is only revealed after several years by statistical evaluation and gives no answer for the individual patient. We here present a method to analyze the response to adjuvant chemotherapy online in individual patients.

Methods/results

In 25 consecutive non-metastatic primary breast cancer patients adjuvant fluorouracil/epirubicin/cyclophosphamid (FEC) or EC followed by taxane (EC-T) or cyclophosphamid/methotrexate/fluorouracil (CMF) therapy were given. Circulating epithelial tumor cells (CETC) were quantified before and after each second cycle of the therapy regimen, between the anthracycline and the taxane block of the regimen and in some cases repeatedly during CMF treatment. Independent of the initial cell number CETC numbers showed a decline, no change or a minor increase in 15 patients of which 14 remained in complete remission and 1 suffered local relapse. Ten patients showed an increase at the end of therapy of which 4 have relapsed during the observation time of between 2 months and up to 54 months. This patient group was compared to a previously published group of 25 patients who have all reached a follow-up of 4.5 years or until relapse.

Conclusion

As in the previous report, Kaplan–Meier analysis revealed a high correlation between the response of CETC to therapy and relapse (p < 0.0001) and curves of both patient groups were super imposable. Multivariate analysis revealed the response of CETC to therapy to be an independent predictive marker for relapse.

Keywords

Increase in number of circulating tumor cells Relapse 

References

  1. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217–220PubMedCrossRefGoogle Scholar
  2. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802PubMedCrossRefGoogle Scholar
  3. Campone M, Fumoleau P, Bourbouloux E, Kerbrat P, Roche H (2005) Taxanes in adjuvant breast cancer setting: which standard in Europe? Crit Rev Oncol Hematol 55:167–175PubMedCrossRefGoogle Scholar
  4. Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J (2005) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. Apr 18:CD003372Google Scholar
  5. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791PubMedCrossRefGoogle Scholar
  6. Ditsch N, Funke I, Mayer B, Untch M (2002) Detection of disseminated tumor cells in bone marrow-currently of no practical therapeutic value. MMW Fortschr Med 144:37–39PubMedGoogle Scholar
  7. Fehm T, Becker S, Pergola-Becker G, Kramer B, Gruber I, Sotlar K, Kurek R, Wallwiener D, Solomayer E (2004) Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. Anticancer Res 24:4211–4216PubMedGoogle Scholar
  8. Feldman M, Stanford R, Catcheside A, Stotter A (2002) The use of a prognostic table to aid decision making on adjuvant therapy for women with early breast cancer. Eur J Surg Oncol 28:615–619PubMedCrossRefGoogle Scholar
  9. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59:3776–3782PubMedGoogle Scholar
  10. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K (2005) The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103:884–891PubMedCrossRefGoogle Scholar
  11. Jones AL (2005) Reduction in mortality from breast cancer. BMJ 330:205–206PubMedCrossRefGoogle Scholar
  12. Lara O, Tong X, Zborowski M, Chalmers JJ (2004) Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol 32:891–904PubMedCrossRefGoogle Scholar
  13. Lobodasch K, Dengler R, Fröhlich F, Rengsberger M, Schubert R, Pachmann U, Pachmann K (2007) Quantification of circulating tumour cells for monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse. Breast 16:211–218PubMedCrossRefGoogle Scholar
  14. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC (1999) Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354:197–202PubMedCrossRefGoogle Scholar
  15. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152–8162PubMedCrossRefGoogle Scholar
  16. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11:3678–3685PubMedCrossRefGoogle Scholar
  17. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF (2003) Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 82:199–206PubMedCrossRefGoogle Scholar
  18. Pachmann K (2005a) Longtime recirculating tumor cells in breast cancer patients. Clin Cancer Res 11:5657; author reply 5657–5658PubMedCrossRefGoogle Scholar
  19. Pachmann U, Pachmann K (2000) Minimale residuale Tumorerkrankung bei soliden epithelialen Tumoren: Neues automatisiertes Analyseverfahren. Dtsch Ärztebl 97(51–52):A-3511Google Scholar
  20. Pachmann K, Heiß P, Demel U, Tilz G (2001) Detection and enumeration of minimal numbers of circulating tumour cells in peripheral blood using Laser Scanning Cytometry (LSC®). Clin Chem Lab Med 39:811–817PubMedCrossRefGoogle Scholar
  21. Pachmann K, Camara O, Kavallaris A, Schneider U, Schünemann S, Höffken K (2005b) Quantification of the response of circulating epithelial cells (CETC) to neodadjuvant treatment of breast cancer: a new tool for therapy monitoring. Breast Cancer Res 7:R975–R979PubMedCrossRefGoogle Scholar
  22. Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, Pouillart P, Thiery JP, Magdelenat H (2004) Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10:1392–1400PubMedCrossRefGoogle Scholar
  23. Rolle A, Günzel R, Pachmann U, Willen B, Höffken K, Pachmann K (2005) Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC® is a predictor for relapse: a preliminary report. World J Surg Oncol 3:18PubMedCrossRefGoogle Scholar
  24. Sawyers CL (2005) Calculated resistance in cancer. Nat Med 11:824–825PubMedCrossRefGoogle Scholar
  25. Solomayer EF, Diel IJ, Salanti G, Hahn M, Gollan C, Schutz F, Bastert G (2001) The independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 7:4102–4108PubMedGoogle Scholar
  26. Tong X, Melnik K, Braun S, Zborowski M, Chalmers JJ (2006) Detection of disseminated tumor cells in bone marrow of breast cancer patients. 6th International Conference on Scientific and Clinical Applications of Magnetic Carriers May 17th–20th. Krems, AustriaGoogle Scholar
  27. Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulias V (2003) Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:849–855PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Katharina Pachmann
    • 1
    • 2
    • 5
  • Robert Dengler
    • 3
  • Kurt Lobodasch
    • 4
  • Frank Fröhlich
    • 4
  • Torsten Kroll
    • 1
  • Matthias Rengsberger
    • 1
  • Rene Schubert
    • 1
  • Ulrich Pachmann
    • 2
  1. 1.Clinic for Internal Medicine II, Friedrich Schiller University JenaJenaGermany
  2. 2.Labor für spezielle Immunhämatologie und GendiagnostikBayreuthGermany
  3. 3.Practice for Internal Medicine, Hematology and OncologyRegensburgGermany
  4. 4.Womens Hospital Deutsches Rot-Kreuz KrankenhausChemnitz-RabensteinGermany
  5. 5.Department of Experimental Hematology and OncologyClinic for Internal Medicine II, Friedrich Schiller Universität JenaJenaGermany

Personalised recommendations